Sepideh Parvanian

Sepideh Parvanian

Auto-generated profile, based on publicly available information

Sepideh Parvanian

Harvard Medical School, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Small Methods
Verified
Journal Article
Open access
RDRiddha Das
Riddha Das
XGXinying Ge
Xinying Ge
FFFan Fei
Fan Fei
SPSepideh Parvanian
Sepideh Parvanian
RWRalph Weissleder
Ralph Weissleder
CGChristopher S. Garris
Christopher S. Garris
Lipid nanoparticles encapsulating mRNA (LNP‐mRNA) revolutionized medicine over the past several years. While clinically approved indications currently focus on infectious disease vaccination, LNP‐mRNA based treatments also hold promise for cancer immunotherapy. However, the route of dosing may impact treatment efficacy, safety, and dose. To minimize adverse effects, it is hypothesized that LNP‐mRNA can be used to activate and engineer dendritic cells (DC) ex vivo before re‐administration of these cells. Here, it is shown that LNP‐mRNA engineered DCs can indeed vaccinate recipient mice. Vaccinated mice showed strong anti‐tumor T cell responses, rejected tumor challenge, and displayed no evidence of toxicity. Further, it is found that DC specific ablation of the immune activating kinase NFkB inducing kinase (NIK) abrogated vaccination efficacy, demonstrating that adoptively transferred DCs can be functionally modified in addition to their antigen presentation capacity. Collectively, these studies show that ex vivo LNP‐mRNA engineering of DCs is a feasible and robust therapeutic strategy for cancer.

15 August 2024 in Journal of Cell Science
Verified
Journal Article
Closed access
PDF file
LCLeila S. Coelho-Rato
Leila S. Coelho-Rato
SPSepideh Parvanian
Sepideh Parvanian
SSSarka Andrs Salajkova
Sarka Andrs Salajkova
OMOhad Medalia
Ohad Medalia
JEJohn E. Eriksson
John E. Eriksson
Intermediate filaments (IFs) comprise a large family of versatile cytoskeletal proteins, divided into six subtypes with tissue-specific expression patterns. IFs have a wide repertoire of cellular functions, including providing structural support to cells, as well as active roles in mechanical support and signaling pathways. Consequently, defects in IFs are associated with more than 100 diseases. In this Cell Science at a Glance article, we discuss the established classes of IFs and their general features, their functions beyond structural support, and recent advances in the field. We also highlight their involvement in disease and potential use as clinical markers of pathological conditions. Finally, we provide our view on current knowledge gaps and the future directions of the IF field.

15 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYisha Liang
Yisha Liang
IEIsabella R. Evavold
Isabella R. Evavold
SPSepideh Parvanian
Sepideh Parvanian
MHMakiko Hayashi
Makiko Hayashi
EGEmerson Glassey
Emerson Glassey
CECharles L. Evavold
Charles L. Evavold
Pyroptosis is a lytic form of cell death executed by gasdermin pores. Through a CRISPR screen to uncover macrophage genes required for gasdermin D (GSDMD) pore activity, we identify the endosome adaptor Rabgef1 as a positive regulator of pore formation. Rabgef1 deficiency preserves NT-GSDMD membrane binding but prevents NT-GSDMD oligomerization and lytic death. Mechanistic analyses revealed that Rabgef1 deficiency is associated with an overabundance of cholesterol in the plasma membrane. Cholesterol depletion or redistribution through multiple approaches restores GSDMD oligomerization and pyroptosis. The Rabgef1-mediated control of membrane cholesterol and pore formation was found to be a general regulator of the gasdermin family. In cancer cells, organoids, and tumors, cholesterol reduction sensitizes resistant cells to GSDME pyroptosis driven by synthetic mRNAs, chemogenetic induction, and chemotherapy treatment. These results establish membrane cholesterol content as an endogenous checkpoint for gasdermin-mediated pyroptotic cell death during the execution phase, with implications for metabolic disease and cancer immunotherapy.